Updates in the management of brain metastases

Neuro-Oncology

Volumn 18, Issue 8, 2016, Pages 1043-1065

  Arvold, Nils D ^a   Lee, Eudocia Q ^b,c   Mehta, Minesh P ^d   Margolin, Kim ^e   Alexander, Brian M ^c,f   Lin, Nancy U ^c,g   Anders, Carey K ^h   Soffietti, Riccardo ⁱ   Camidge, D Ross ^j   Vogelbaum, Michael A ^k   Dunn, Ian F ^c,f   Wen, Patrick Y ^b,c  

^a UNIVERSITY OF MINNESOTA DULUTH   (United States)

^b Dana Farber Cancer Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Brain metastases; Chemotherapy; Stereotactic radiosurgery; Surgery; Whole brain radiation

Indexed keywords

ALECTINIB; B RAF KINASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CERITINIB; CORTICOSTEROID; CRIZOTINIB; DABRAFENIB; IPILIMUMAB; LAPATINIB; NIVOLUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG POTENCY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; OVERALL SURVIVAL; QUALITY OF LIFE; RADIATION NECROSIS; RADIATION SAFETY; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT PLANNING; WHOLE BRAIN RADIOTHERAPY; ADULT; ADVERSE DRUG REACTION; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); COGNITION; DRUG THERAPY; FEMALE; MALE; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RADIOTHERAPY; SECONDARY; SKULL IRRADIATION; TREATMENT OUTCOME;

ADULT; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COGNITION; CRANIAL IRRADIATION; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84982102697     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now127     Document Type: Review

References (166)

1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75(1):5-14
2. Sawaya R, Bindal R, Lang F, et al. Metastatic brain tumors. In: Kaye A, Laws E, eds. Brain tumors: an encyclopedic approach. 2nd ed. London: Churchill Livingstone; 2001:999-1026
3. Fox BD, Cheung VJ, Patel AJ, et al. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):1-6
4. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-2872
5. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648-1655
6. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2100-2108
7. Ajithkumar T, Parkinson C, Fife K, et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13): e486-e497
8. Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17): 1881-1888
9. Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther. 2012;13(14):1376-1383
10. Takeda M, Okamoto I, Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol. 2013;8(5):654-657
11. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807-1814
12. Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013; 14(3):244-248
13. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site. Available at: www.nccn.org. Accessed May 3, 2016
14. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751
15. Nieder C, Mehta MP. Prognostic indices for brain metastases-usefulness and challenges. Radiat Oncol. 2009;4:10
16. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosisspecific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-425
17. Sperduto PW, Yang TJ, Beal K, et al. The effect of gene mutations on survival in patients with adenocarcinoma of the lung following the development of brain metastases. Int J Radiat Oncol Biol Phys. 2015;93(3):S37-S39
18. Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with alk-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016; 34(2):123-129
19. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395
20. Liu Y, Alexander BM, Chen YH, et al. Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. J Neurooncol. 2015; 124(3):429-437
21. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810-3816
22. Kondziolka D, Parry PV, Lunsford LD, et al. The accuracy of predicting survival in individual patients with cancer. J Neurosurg. 2014;120(1):24-30
23. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645
24. Dyer MA, Kelly PJ, Chen YH, et al. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys. 2012;83(4):e479-e486
25. Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012;14(7):910-918
26. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1-9
27. Brown PD, Asher AL, Ballman KV, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol. 2015;33(suppl):abstr LBA4
28. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491
29. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141
30. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485-1489
31. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-1044
32. American Society for Radiation Oncology. 2014 Choosing Wisely List. Available at: https://www.astro.org/Patient-Care/ Patient-Education/2014-Choosing-Wisely-List/. Accessed May 3, 2016
33. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710-717
34. Arvold ND, Catalano PJ. Local therapies for brain metastases, competing risks, and overall survival. Int J Radiat Oncol Biol Phys. 2015;91(4):718-720
35. Aoyama H, Tago M, Shirato H, Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015;1(4):457-464
36. Sahgal A. Point/counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care? Neuro Oncol. 2015;17(7):916-918
37. Mehta MP. The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro Oncol. 2015; 17(7):919-923
38. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37-46
39. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210-225
40. Bhangoo SS, Linskey ME, Kalkanis SN, American Association of Neurologic Surgeons, Congress of Neurologic Surgeons. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am. 2011;22(1):97-104, viii
41. Grandhi R, Kondziolka D, Panczykowski D, et al. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases. J Neurosurg. 2012;117(2):237-245
42. University of California, San Francisco. Neurocognitive outcomes in patients treated with radiotherapy for five or more brain metastases (NAGKC 12-01). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2012-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/ NCT01731704. NLM Identifier: NCT01731704
43. MD Anderson Cancer Center. A prospective phase iii trial to compare stereotactic radiosurgery versus whole brain radiation therapy. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2012-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/NCT01592968. NLM Identifier: NCT01592968
44. Nath SK, Lawson JD, Simpson DR, et al. Single-isocenter frameless intensity-modulated stereotactic radiosurgery for simultaneous treatment of multiple brain metastases: clinical experience. Int J Radiat Oncol Biol Phys. 2010;78(1):91-97
45. Huang Y, Chin K, Robbins JR, et al. Radiosurgery of multiple brain metastases with single-isocenter dynamic conformal arcs (SIDCA). Radiother Oncol. 2014;112(1):128-132
46. Thomas EM, Popple RA, Wu X, et al. Comparison of plan quality and delivery time between volumetric arc therapy (RapidArc) and Gamma Knife radiosurgery for multiple cranial metastases. Neurosurgery. 2014;75(4):409-417;discussion 417-408
47. Thomas A, Niebanck M, Juang T, et al. A comprehensive investigation of the accuracy and reproducibility of a multitarget single isocenter VMAT radiosurgery technique. Med Phys. 2013;40(12):121725
48. Hsu F, Carolan H, Nichol A, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys. 2010; 76(5):1480-1485
49. Arvold ND, Pinnell NE, Mahadevan A, et al. Steroid and anticonvulsant prophylaxis for stereotactic radiosurgery: Large variation in physician recommendations [published online Nov 10 2015]. Pract Radiat Oncol. 2015. doi:10.1016/j.prro. 2015.11.004
50. Kwon AK, Dibiase SJ,Wang B, et al. Hypofractionated stereotactic radiotherapy for the treatment of brain metastases. Cancer. 2009;115(4):890-898
51. Rajakesari S, Arvold ND, Jimenez RB, et al. Local control after fractionated stereotactic radiation therapy for brain metastases. J Neurooncol. 2014;120(2):339-346
52. Soffietti R, Ruda R, Trakul N, et al. Point/counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis? Neuro Oncol. 2016;18(1):12-15
53. Soltys SG, Adler JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2008;70(1):187-193
54. Jagannathan J, Yen CP, Ray DK, et al. Gamma Knife radiosurgery to the surgical cavity following resection of brain metastases. J Neurosurg. 2009;111(3):431-438
55. Kelly PJ, Lin YB, Yu AY, et al. Stereotactic irradiation of the postoperative resection cavity for brain metastasis: a frameless linear accelerator-based case series and review of the technique. Int J Radiat Oncol Biol Phys. 2012;82(1):95-101
56. Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys. 2012;84(2):336-342
57. Atalar B, Modlin LA, Choi CY, et al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2013;87(4):713-718
58. Ojerholm E, Lee JY, Thawani JP, et al. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg. 2014;121(Suppl): 75-83
59. Minniti G, Esposito V, Clarke E, et al. Multidose stereotactic radiosurgery (9 Gy×3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys. 2013;86(4):623-629
60. Wang CC, Floyd SR, Chang CH, et al. Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy× 3 daily fractions regimen. J Neurooncol. 2012;106(3):601-610
61. M.D. Anderson Cancer Center. Resection bed post-surgical stereotactic radiosurgery (SRS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2009-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/ NCT00950001. NLM Identifier: NCT00950001
62. Alliance for Clinical Trials in Oncology. Stereotactic radiosurgery or whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2011-[cited 2015 Nov 2]. Available from: http:// clinicaltrials.gov/show/NCT01372774. NLM Identifier: NCT01372774
63. Patel KR, Burri SH, Asher AL, et al. Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery. 2015. [Epub ahead of print]
64. Gondi V, Paulus R, Bruner DW, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656-664
65. Monaco EA III, Faraji AH, Berkowitz O, et al. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer. 2013;119(1):226-232
66. Li J, Bentzen SM, Li J, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71(1):64-70
67. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72
68. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437
69. NRG Oncology. Memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with brain metastases. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2015-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/NCT02360215. NLM Identifier: NCT02360215
70. Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a phase iii randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653-1659
71. Ropper AH, Samuels MA. Intracranial neoplasms and paraneoplastic disorders. In: Ropper AH, Samuels MA, eds. Adams and Victor's Principles of Neurology. 10th ed. New York, NY: McGraw-Hill; 2014
72. Nonoguchi N, Miyatake S, Fukumoto M, et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: Pathological consideration of their potential roles. J Neurooncol. 2011;105(2):423-431
73. Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys. 2013;87(3):449-457
74. Stockham AL, Tievsky AL, Koyfman SA, et al. Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol. 2012; 109(1):149-158
75. Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol. 2010;99(1):81-88
76. Horky LL, Hsiao EM, Weiss SE, et al. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103(1): 137-146
77. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270-e278
78. Du Four S, Wilgenhof S, Duerinck J, et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer. 2012;48(16): 3045-3051
79. Liebner DA, Walston SA, Cavaliere R, et al. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res. 2014;24(2):172-176
80. Parker GM, Dunn IF, Ramkissoon SH, et al. Recurrent radiation necrosis in the brain following stereotactic radiosurgery. Pract Radiat Oncol. 2015;5(3):e151-e154
81. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487-1495
82. Alliance for Clinical Trials in Oncology.Corticosteroids + bevacizumab vs. corticosteroids + placebo (best) for radionecrosis after radiosurgery for brain metastases. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2015-[cited 2015 Nov 2]. Available from: http ://clinicaltrials.gov/show/NCT02490878. NLM Identifier: NCT02490878
83. Torres-Reveron J, Tomasiewicz HC, Shetty A, et al. Stereotactic laser induced thermotherapy (LITT): a novel treatment for brain lesions regrowing after radiosurgery. J Neurooncol. 2013; 113(3):495-503
84. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869
85. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):71-83
86. Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013; 31(7):895-902
87. Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013;85(5):1312-1318
88. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128(4):214-218
89. Cao KI, Lebas N, Gerber S, et al. Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Ann Oncol. 2015;26(1):89-94
90. National Cancer Institute. Whole-brain radiation therapy with or without lapatinib ditosylate in treating patients with brain metastasis from HER2-positive breast cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2012-[cited 2015 Jul 27]. Available from: http://clinicaltrials.gov/show/NCT01622868. NLM Identifier: NCT01622868
91. Lin NU, Freedman RA, Ramakrishna N, et al. A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013;142(2): 405-414
92. Tsimberidou AM, Letourneau K, Wen S, et al. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD Anderson Cancer Center experience. Clin Cancer Res. 2011; 17(12):4110-4118
93. Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013;14(10):e396-e406
94. Lin NU,Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14(10):e407-e416
95. Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015;17(9):1188-1198
96. Preusser M, Berghoff AS, Schadendorf D, et al. Brain metastasis: opportunity for drug development? Curr Opin Neurol. 2012;25(6): 786-794
97. Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100-104
98. van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1-12
99. Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19(23):6404-6418
100. Camidge DR. Taking aim at ALK across the blood-brain barrier. J Thorac Oncol. 2013;8(4):389-390
101. ShiW, Dicker AP. CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol. 2016; 34(2):107-109
102. Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol. 1989;7(4): 319-328
103. Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. J Natl Cancer Inst. 1988; 80(15):1211-1216
104. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664-5678
105. Morikawa A, Peereboom DM, Thorsheim HR, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol. 2015;17(2):289-295
106. Parrish KE, Sarkaria JN, Elmquist WF. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin Pharmacol Ther. 2015;97(4):336-346
107. Lin NU, Gabrail NY, Sarantopoulos J, et al. Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. ASCO Meeting Abstracts. 2014;32(15-suppl):2523
108. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18(4):938-944
109. Clarke JL, PaoW,Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99(2): 283-286
110. Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant nonsmall cell lung cancer. Neuro Oncol. 2011;13(12):1364-1369
111. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465
112. Heller KN, Pavlick AC, Hodi FS, et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. ASCO Meeting Abstracts. 2011;29(15-suppl):8581
113. Italian Network for Tumor Biotherapy Foundation. A study of fotemustine (FTM) vs FTM and ipilimumab (IPI) or IPI and nivolumab in melanoma brain metastasis (NIBIT-M2). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2015-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/NCT02460068. NLM Identifier: NCT02460068
114. Bristol-Myers Squibb. A multi-center phase 2 open-label study to evaluate safety and efficacy in subjects with melanoma metastatic to the brain treated with nivolumab in combination with ipilimumab followed by nivolumab monotherapy (CheckMate 204). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014-[cited 2015 Jun 22]. Available from: http://clinicaltrials.gov/show/NCT02320058. NLM Identifier: NCT02320058
115. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269-278
116. Lin NU, Gelman RS, YoungerWJ, et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). ASCO Meeting Abstracts. 2013; 31(15-suppl):513
117. Besse B, Le Moulec S, Mazie res J, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase ii study. Clin Cancer Res. 2015;21(8): 1896-1903
118. Centre Hospitalier Intercommunal Creteil. Comparison of two therapeutic strategies in patients with non-squamous non-small cell lung cancer (NSCLC) with asymptomatic brain metastases (METAL2). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/NCT02162537. NLM Identifier: NCT02162537
119. Stricker T, Arteaga CL. Drug-resistant brain metastases: a role for pharmacology, tumor evolution, and too-late therapy. Cancer Discov. 2015;5(11):1124-1126
120. Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015; 5(11):1164-1177
121. Paik PK, Shen R, Won H, et al. Next-generation sequencing of stage iv squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov. 2015;5(6): 610-621
122. Steeg PS. Perspective: the right trials. Nature. 2012;485(7400): S58-S59
123. Boggs DH, Robins HI, Langer CJ, et al. Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014; 15(6):433-440
124. Palmieri D, Duchnowska R, Woditschka S, et al. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res. 2014;20(10):2727-2739
125. Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406-4414
126. Pivot X, Manikhas A, Zurawski B, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564-1573
127. National Comprehensive Cancer Network. Central Nervous System Cancers (Version 1.2015). 2015; http://www.nccn.org/ professionals/physician-gls/pdf/cns.pdf. Accessed May 3, 2016
128. Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33(30):3475-3484
129. Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136(1):153-160
130. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12): 2972-2977
131. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459
132. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71
133. Cortes J, Dieras V, Ro J, et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015;16(16):1700-1710
134. Freedman RA, Gelman RS, Wefel JS, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase ii trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945-952
135. Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016. doi: 10.1001/jamaoncol.2016.0237
136. Bartsch R, Berghoff AS, Vogl U, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729-737
137. Lim E, Lin NU. Updates on the management of breast cancer brain metastases. Oncology (Williston Park). 2014;28(7): 572-578
138. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-1095
139. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39
140. GlaxoSmithKline. Study to evaluate treatment of dabrafenib plus trametinib in subjects with braf mutation-positive melanoma that has metastasized to the brain. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2013-[cited 2015 Nov 2]. Available from: http://clinicaltrials. gov/show/NCT02039947. NLM Identifier: NCT02039947
141. University of Pittsburgh. Phase II study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (CoBRIM-B). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/ NCT02230306. NLM Identifier: NCT02230306
142. Kluger HM, Goldberg S, Sznol M, et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol. 2015;33(suppl):abstr 9009
143. Fuerst ML. Pembrolizumab induces responses in melanoma patients with brain mets. In Cancer Network [Internet]. Published 2015 Nov 22. Cited 18 Feb 2016. Available from: http://www.cancernetwork.com/smr-2015/pembrolizumabinduces-responses-melanoma-patients-brain-mets
144. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-133
145. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017
146. Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer. 2010;68(2):264-268
147. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15(7):1042-1047
148. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993-999
149. Dempke WC, Edvardsen K, Lu S, et al. Brain metastases in NSCLC: are TKIs changing the treatment strategy? Anticancer Res. 2015; 35(11):5797-5806
150. Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16(13):e510-e521
151. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394
152. Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5): 1023-1028
153. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128
154. Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016. doi: 10.1016/S1470-2045 (15)00614.2
155. Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase ii global study. J Clin Oncol. 2016;34(7):661-668
156. Novartis. A phase II Study to evaluate the efficacy and safety of oral ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or to leptomeninges (Ascend-7). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2015-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/ show/NCT02336451. NLM Identifier: NCT02336451
157. Hoffmann-La Roche. ALEX study: a randomized, phase III study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase-positive advanced non-small cell lung cancer participants. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014-[cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/show/NCT02075840. NLM Identifier: NCT02075840
158. Yale University. MK-3475 in melanoma and NSCLC patients with brain metastases. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014-[cited 2015 Jun 22]. Available from: https://www.clinicaltrials.gov/ct2/show/ NCT02085070. NLM Identifier: NCT02085070
159. Bristol-Myers Squibb. Study of nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2011-[cited 2016 Feb 18]. Available from: http://clinicaltrials.gov/show/NCT01454102. NLM Identifier: NCT01454102
160. Yale University. Pembrolizumab plus bevacizumab for treatment of brain metastases in metastatic melanoma or non-small cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2016-[cited 2016 Feb 18]. Available from: https://www.clinicaltrials.gov/ct2/show/ NCT02681549. NLM Identifier: NCT02681549
161. Guerrieri M, Wong K, Ryan G, et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004;46(1):107-111
162. Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery. 1991;28(2):201-205
163. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20(17):3644-3650
164. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005; 61(1):185-191
165. Knisely JP, Berkey B, Chakravarti A, et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008;71(1):79-86
166. Neuhaus T, Ko Y, Muller RP, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009;100(2): 291-297